

BERISA HASANBEGOVIC

MD, PhD, Internal medicine specialist, Medical oncology subspecialist
Academic Specialist in Nutrition
Assistant Professor

E-mail: berisa.hasanbegovic@ssst.edu.ba, berisa.hasanbegovic@gmail.com

Date & place of birth: 27-Jun-1975, Sarajevo, B&H

1. RESEARCH INTEREST

Breast, gynecological and lung cancer: systemic oncologic treatment in neoadjuvant, adjuvant and metastatic setting; cancer immunotherapy, nutrition in cancer.

2. EDUCATION

02/2024	PhD, Medical faculty Sarajevo, University of Sarajevo, topic: breast cancer
03/2023	Academic Specialist in Nutrition, Interdisciplinary Study Center, University of Sarajevo
05/2016	Medical oncology subspecialist
2016-2018	Doctoral study, Medical faculty Sarajevo, University of Sarajevo
10/2011	MSc, Medical faculty Sarajevo, University of Sarajevo, topic: breast cancer
04/2010.	Internal medicine specialist
07/2003.	MD, State exam
1993 – 2002.	Medical faculty Sarajevo, University of Sarajevo
1989-1993.	Highschool 2 nd Gymnasium Sarajevo

3. WORK EXPERIENCE

2024- presence	SSST University, Assistant Professor, Clinical Oncology
2019-2024:	SSST University, Senior Teaching Assistant, Clinical Oncology
2004-presence:	Oncology Clinic, Clinical University Center Sarajevo Internal medicine specialist, Medical oncology department, since April 2010 Internal medicine resident, 2006-2010.; MD, Medical oncology department, 2004.-2006.
2002 – 2004:	Pharmaceutical company Bosnalijek Sarajevo Medical assistant, Medical-informative service, Domestic Marketing Division

4. TEACHING EXPERIENCE

Assistant Professor, Oncology, Medicine, SSST University (2024-present)

Senior Teaching Assistant, Oncology, Medicine, SSST University (2019-2024)

Expert from practice, Oncology, Medicine, SSST University (2018-2019)

Student-assistent, Institute for anatomy, Medical faculty Sarajevo (1996-1997)

Student-assistent, Institute for biochemistry, Medical faculty Sarajevo (1996-1999)

5. PROFESSIONAL DEVELOPMENT

ESMO (*European Society of Medical Oncology*) member since 2005

- **3rd Sarajevo Breast Cancer Conference (2005), B&H**
- ESEC 2005, Budapest, Hungary (2005)
- ESPEN basic course of enteral and parenteral nutrition, Vilnius, Lithuania (2005)
- 6th International Workshop on Molecular Targeted Therapy of Cancer, Cracow, Poland (april 2006)
- 31st ESMO Congress, Istanbul, Turkey (2006)
- International pain course-Improving pain education supported by Education Committee of IASP chapters, Sarajevo, B&H (March 2007)
- **1st International Breast Cancer Conference, Sarajevo, B&H (April 2007)**
- 2nd Seminar of Balcan Union of Oncology, Volos, Greece (September 2007)
- 7th Masterclass in clinical oncology, Sofia, Bulgaria, ESO grant (March 2008)
- 10th World Congress of gastrointestinal cancer, Barcelona, Spain (June 2008)
- Basic abdominal ultrasound school, Sarajevo, B&H, (2008)
- Salzburg Weill Cornell/MSKCC Oncology Seminar, Salzburg, Austria (2008)
- **2nd International Breast Cancer Conference, Sarajevo, B&H (April 2009)**
- Salzburg Internal medicine Seminar, Salzburg, Austria (June 2009)
- 3rd Seminar of Balcan Union of Oncology, Volos, Greece (September 2009)
- Joint 15th ECCO/34th ESMO Congress, Berlin, Germany (September 2009)
- 35th ESMO Congress, Milan, Italy (October 2010)
- 1st. International Conference of head and neck and lung cancer, Athens, Greece (March 2011)
- 16th. ECCO/36th. ESMO Congress, Stockholm, Sweden (September 2011)
- State of the Art Lung Cancer Preceptorship Meeting, Institut Gustave Roussy, Pariz, 24 – 25 November 2011
- 8th European Conference of breast cancer, Vienna, Austria (March 2012)
- 3rd European Conference of lung cancer, Geneve, Switzerland (April 2012)
- 39th ESMO Congress, Madrid, Spain (September 2014)

- 14th St. Gallen International Breast Cancer Conference, Primary Therapy of Early Breast Cancer, Vienna, Austria (March 2012)
- 7th days of Bosnian-Herzegovinian Academy of Arts and Sciences (BHAAAAS) (Brcko, B&H, April 2015)
- 1st Sarajevo Winter Oncology Conference (Sarajevo, B&H, December 2015)
- 41st ESMO Congress, Copenhagen, Denmark (October 2016)
- 8th French-Serbian Oncology Congress, Novi sad, Serbia (april 2017)
- 42nd ESMO Congress, Madrid, Spain (September 2017)
- 3rd Sarajevo Winter Oncology Conference (Sarajevo, B&H, December 2017)
- YOAI (Young oncologist academy on immunotherapy, BH Oncologic Society), Sarajevo, B&H (March 2018)
- YOAI (Young oncologist academy on immunotherapy, BH Oncologic Society), Sarajevo, B&H (September 2018)
- 4th Sarajevo Winter Oncology Conference (Sarajevo, B&H, November 2018)
- YOAI (Young oncologist academy on immunotherapy, BH Oncologic Society), Sarajevo, B&H (March 2019)
- 10th French-Serbian Oncology Congress, Novi sad, Serbia (april 2019)
- YOAI (Young oncologist academy on immunotherapy, BH Oncologic Society), Sarajevo, B&H (September 2019)
- ESMO Congress, Barcelona, Spain (September 2019)
- Breast cancer Preceptorship, Portugal (October 2019)
- 5th Sarajevo Winter Oncology Conference (Sarajevo, B&H, December 2019)
- Global Expert Meeting 3rd edition, Berlin, Germany (2022)
- ESMO Congress, Paris, France, (2022)
- St Gallen Breast Cancer Conference, Vienna, Austria (2023)
- ESMO Breast Cancer, online, Berlin, Germany (2023)
- ESMO Congress, Madrid, Spain (2023)
- ESO Refresher Course on Gynecological Cancers, Sarajevo, B&H (2023)
- Breast Cancer Preceptorship Meeting, Oncology Institute Ljubljana, Slovenija (2023)
- ELCC, Prague, Czech Republic (2024)
- EBCC, Berlin, Germany (2024)
- ESMO Gynecological cancers, Florence, Italy (2024)
- ESMO Congress, Barcelona, Spain (September 2024)

6. FUNDED PROJECTS

Participation in clinical studies:

1. 2005 – CECOG/GIST 1.2.001, metastatic GIST, phase III (subInvestigator);

2. 2005 – metastatic colorectal cancer phase II (subInvestigator);
3. 2006 – CECOG/Core 1.2.001, metastatic colorectal cancer phase II (subInvestigator);
4. 2008 –C-II-005, metastatic colorectal cancer phase II (subInvestigator);
5. 2008 – CECOG /CORE 1.2.002, metastatic colorectal cancer phase II (subInvestigator);
6. 2008 – CECOG/BC1.3.005, breast cancer phase III (subInvestigator);
7. 2008 - BO20289, breast cancer phase III (subInvestigator);
8. 2009 - BO20906, breast cancer phase III (subInvestigator);
9. 2009 - BO20231, breast cancer phase III (subInvestigator);
10. 2010- MO22224, ovarian cancer phase III (subInvestigator);
11. 2010 – BO22589 ,breast cancer phase III (subInvestigator);
12. 2010 - BO21977, breast cancer phase III (subInvestigator);
13. 2011- NCT01348126, lung cancer phase IIB/III (subInvestigator);
14. 2014 - BO28407, breast cancer phase III (subInvestigator);
15. 2014 - SB3-G31--BC, breast cancer phase III (Principal Investigator);
16. 2014 - TRIO-020, breast cancer phase III (subInvestigator);
17. 2015 - BO28984, lung cancer phase III (subInvestigator);
18. 2016 - WO29522, breast cancer phase III (subInvestigator);
19. 2016 - GO29058, breast cancer phase III (subInvestigator);
20. 2016 - MYL14020, lung cancer phase III (Principal Investigator);
21. 2018 - MO39193, breast cancer phase III (Principal Investigator)
22. 2020- ZN-c5-001, breas cancer phase I/II (subinvestigator)
23. 2020- JTX-4014-202, lung cancer, phase II (subinvestigator)
24. 2022-GO42784, breast cancer, phase III (subinvestigator)
25. 2024-BO28984, lung cancer, phase III (subinvestigator)

7. PUBLICATIONS

a) Original scientific papers

- a) Pasic A, Ceric T, Beslija S, Banjin M, **Salkic B**, Sosevic A. Internet technology and multidisciplinary approach to cancer patients at Institute of oncology Sarajevo ESO Conference on Managing cancer service 2005 Milan , Italy
- b) **Salkić B**, Banjin M, Sosevic A, Pasic A, Ceric T, Beslija S. Time to progression in patients with metastatic CRC treated with irinotecan or capecitabine as first line treatment (retrospective study). ESEC (ESMO Scientific & Educational Conference) 2005 Budapest Hungary
- c) Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, **Salkic B**. A Single Institution Randomized Trial of Taxotere (T) and Xeloda (X) Given in Combination vs. Taxotere (T) followed by Xeloda (X) after progression as First Line Chemotherapy (CT) for Metastatic Breast Cancer (MBC). EJC suppl.2005; 3(2):114-114.
- d) Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, **Salkic B**. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). JCO, 2006; 24 (18, part1 suppl): 20S-20S.
- e) Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, Banjin M, Cardzic A, Sosevic A, Pasic A, Ceric T, **Salkic B**. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). ASCO(American Asociation for clinical oncology) Annual Meeting Proceedings Part I. 2006 Vol 24, No. 18S (Supplement),: 571
- f) Beslija S, Banjin M, Jungic S, Obralic N, Kecman-Malcic G, Rakita I, **Salkic B**, Pasic A, Tinjic L, Smoljanovic V. Update phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC). JCO, 2009 ASCO Annual Meeting, Vol 27, No 15S, 2009:e15064;
- g) **Hasanbegovic B**, Basic H, Obralic N, Beslija S. Influence of taxane-based adjuvant chemotherapy in early breast cancer patients on disease free survival. Folia Medica Facultatis Medicinae Universitatis Saraeviensis;2012, Vol. 47 Issue 1, p79.
- h) Ceric T, **Hasanbegović B**, Bašić-Čabaravdić. Is individually tailored therapy becomes reality? In: Lincender-Cvijetić L, Bašić-Čabaravdić H, urednici. Contemporary approach in breast cancer therapy. Sarajevo: BH Science and Art Academy, book 41; November 2012.
- i) Pašic A, **Hasanbegović B**, Bešlija S, Delić T. Informations for ovarian cancer patients. B&H Oncology Society, 2013.
- j) Bešlija S, Vrbanec D. Medicinska/internistička onkologija, 2014.
 - A. Poglavlje Gastrointestinalne komplikacije
 - B. Poglavlje Mučnina i povraćanje
 - C. Poglavlje Metabolički problemi

D. Poglavlje Karcinom tijela materice.

- k) Pasic, S. Beslija, A. Djuran, I. Sefic-Pasic, M. Banjin, T. Ceric, A. Rasic, **B. Hasanbegovic**, A. Jalovcic, E. Kapisazovic. Correlation between of expression of the enzyme topoisomerase I and p53 and result of irinotecan based therapy in patients with metastatic colorectal cancer. *Annals of Oncology* 26 (Supplement 4): iv1–iv100, 2015.
- l) Faruk Skenderi, Nurija Bilalovic, Vanesa Beslagic, Edina Balta, **Berisa Hasanbegovic**, Semir Beslija, Semir Vranic. Neuroendocrine carcinoma of the breast: A retrospective review 2005-2016. *Folia medica* 2016; 51 supp 1, p33.
- m) S Beslija, T Ceric, **B Hasanbegovic**, A Kurtović-Kozaric, A Pasic, N Mahic. 176P Clinical Outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ml25232 study. *Annals of Oncology* 28 (suppl 5), 2017.
- n) S Beslija, A Pasic, E Kapisazovic, **B Hasanbegovic**, E Sokolovic, F Skenderi, and T Ceric. Neoadjuvant trastuzumab + pertuzumab in HER2 positive breast cancer in a country with limited resources: Evaluation of complete pathological response in a real world practice. *Journal of Clinical Oncology* 2018 36:15_suppl, e12661-e12661.
- o) Rašić, A., Sofić, A., Bešlija, S., Rašić, I., & **Hasanbegović, B.** (2019). Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer. *Medicinski Glasnik*, 16(1).
- p) Imamovic, D. , Bilalovic, N. , Skenderi, F. , Beslagic, V. , Ceric, T. , **Hasanbegovic, B.** , Beslija, S. and Vranic, S. A clinicopathologic study of invasive apocrine carcinoma of the breast: A single-center experience. *Breast J.* 2018 . doi:10.1111/tbj.13140
- q) Eminagić, D., Lokvančić, A., **Hasanbegović, B.**, Mekić-Abazović, A., Avdičević, A., Marijanović, I., ... & Kapo, B. (2019). Efficacy and safety of local lysozyme treatment in patients with oral mucositis after chemotherapy and radiotherapy. *Acta Pharmaceutica*, 69(4), 695-704.
- r) Dzinic SH, Mahdi Z, Bernarrdo MM, Vranic S, Beydoun H, Nahra N et al. Maspin differential expression patterns as a potential marker for targeted screening og oesophageal adenocarcinoma/gastroesophageal junction adneocarcinoma. *PLoS ONE* 2019; 14(4): e0215089.
- s) Beslija, S., Ceric, T., **Hasanbegovic, B.**, Skenderi, F., Alidžanović, J, Koprić, D., Marjanović, I et al. (2019). 200PEffects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results. *Annals of Oncology*. 30. 10.1093/annonc/mdz240.025.
- t) Banjin M. Melanom, 2018.
A. Poglavlje Melanom kod pacijenata u trećoj životnoj dobi
- u) Bešlija S, Vrbanec D. Internistička onkologija, 2.prošireno izdanje 2019.
A. Poglavlje Gastrointestinalne komplikacije
B. Poglavlje Mučnina i povraćanje

- C. Poglavlje Metabolički problemi
 - D. Poglavlje Karcinom tijela materice
 - E. Poglavlje Onkološki tretman pacijenata sa dijabetesom
 - F. Poglavlje Onkološki tretman pacijenata sa hepatalnom disfunkcijom
 - G. Poglavlje Onkološki tretman pacijenata sa hepatitisom
- v) Milardovic R, Beslic N, Ceric S, Sadija A, Kristic S, **Hasanbegovic B**. Positron Emission Tomography Scan (PET/CT) During the COVID-19 Pandemic: a Case Series. *Acta Inform Med*. 2020;28(4):292-297. doi:10.5455/aim.2020.28.292-297.
- w) Cerić, T., Sokolović, E., **Hasanbegović, B.**, Pašić, A., Gojković, Z., Mašić, J. V., ... & Bešlija, S. (2022). The Oncology Association of Bosnia and Herzegovina's recommendations for fertility preservation in oncologic patients. *Bosnian Journal of Basic Medical Sciences*. 22. 10.17305/bjbms.2021.6977.
- x) Cerić, T., Sokolović, E., Pašić, A., Borovac-Gurda, E., Smajlbegović, V., **Hasanbegović, B.**, ... & Bešlija, S. (2022). Acceptance, effects, and tolerability in the vaccination process against SARS-CoV-2 among cancer patients in Bosnia and Herzegovina: a single-center cross-sectional study. *Bosnian Journal of Basic Medical Sciences*. 22. 10.17305/bjbms.2021.7134.
- y) **Hasanbegović, B.**, Medić, B. S., Sokolović, E., Tomić, N., & Pojskić, L. (2023). RS17817449 FTO gene variation associated with familial disease burden rather than individual risk for breast cancer. *Journal of Health Sciences*. 10.17532/jhsci.2023.2164.

b) Conferences, presentations, abstracts, proceedings

Invited speaker :

- Treatment of side effect of oncologic therapy. B&H Oncology Society, Sarajevo, December 2013.
- Contemporary approach in ovarian cancer treatment. B&H Oncology Society, Sarajevo, December 2014.
- 7. BHAAAS Days in BiH. Tretman karcinoma dojke sa negativnim receptorima (triple-negative) (Brcko, BiH April 2015.)
- 1st B&H Endocrinology and diabetes congress with international participation (Sarajevo, B&H, April 2015)
- 1st Sarajevo Winter Oncology Conference. Treatment of HER2 positive metastatic breast cancer (Sarajevo, B&H, December 2015)
- ESMO 2017. Poster presentation 176P Clinical Outcomes of delayed start of trastuzumab treatment in patients with early breast cancer: ML25232 study
- 3rd Sarajevo Winter Oncology Conference. Treatment of HER2 positive metastatic breast cancer-2nd line; Endocrine therapy in premenopausal breast cancer patients (Sarajevo, B&H, December 2017)
- YOAI (Young oncologist academy on immunotherapy, BH Oncologic Society), Sarajevo, B&H (March 2018)
- YOAI (Young oncologist academy on immunotherapy, BH Oncologic Society), Sarajevo, B&H (September 2018)
- 4th Sarajevo Winter Oncology Conference. Endocrine therapy in premenopausal breast cancer patients (Sarajevo, B&H, November 2018).

- ESMO 2019. Poster presentation 200P - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, HER2 positive breast cancer in a limited resources setting: ML25232 study final results.
- YOAI (Young oncologist academy on immunotherapy, BH Oncologic Society), Sarajevo, B&H (March 2019)
- YOAI (Young oncologist academy on immunotherapy, BH Oncologic Society), Sarajevo, B&H (September 2019)
- 5th Sarajevo Winter Oncology Conference.(Sarajevo, B&H, December 2019)
- 6th Sarajevo Winter Oncology Conference.(Sarajevo, B&H, December 2020).
- HDIO, Rovinj, Croatia, 2022
- 8th Sarajevo Winter Oncology Conference.(Sarajevo, B&H, December 2022)
- ESO Refresher Course on Gynecological cancers (Sarajevo, B&H, Nov 2023)
- 9th Sarajevo Winter Oncology Conference.(Sarajevo, B&H, December 2023)